Regenerative Medicine Research Center

Sichuan University West China Hospital Regenerative Medicine Research Center, established in 2009, is one of the key interdiscipline center in Sichuan University. The Director is Dr. Y. James Kang Who is the perfessor of The first China National thousand person plan.
Dr. Kang received Ph.D. in Toxicology and Zoology (Cell Biology) from Iowa State University in 1989 and completed postdoctoral training in Biochemistry and Molecular Biology at Cornell University Medical Center in 1990. He was Assistant Professor of Pharmacology and Toxicology, University of North Dakota School of Medicine (1991-1996); Associate Professor of Medicine, Pharmacology and Toxicology and University Scholar, University of Louisville School of Medicine (1996-2001), then promoted to Professor and Distinguished University Scholar (2001-); and has served as the director of the RMRC since 2009. He had served several NIH study sections from 1997 to 2006, and other federal agencies including USDA, US-EPA and US-Veterans Administrations from 1996 to 2005. He was elected as Fellow of the Academy of Toxicological Sciences in 2001. He is the Editor-in-Chief of the Cardiovascular Toxicology journal, the Editor of the book series of Methods in Pharmacology and Toxicology. He also served as Associate Editors for Experimental Biology and Medicine, and the Journal of Health Science, and council member for several scientific societies nationally and internationally. His research interests are in regenerative medicine, focusing on cardiovascular regeneration, as well as dietary manipulation of cardiovascular disease, liver fibrosis and cirrhosis, oxidative stress and antioxidant mechanisms, metallothionein and glutathione, and non-human primate models for human diseases. 
Regenerative Medicine Research center has faculty and staff of 53. Among them, there are 50 senior faculty members, 53 mentors for Ph.D.. And our center has eight open technical platforms, including tissue culture platform, protein engineering platform, molecular biology platform, pathological platform, metabolomics platform, hemorheology platform, biomaterial platform and pharmacological platform. Platforms are open to the whole hospital, university and other universities.
The center now consists of five laboratories. including:
1、Key Laboratory of Transplant Engineering and Immunology, Ministry of Health, West China Hospital, Sichuan University
  In 1996,Professor Youping Li was required to come back from starzle institute of organ transplantation, Pittsburgh University, to construct the Lab of Transplant Immunology, an opening lab of West China Hospital. In continuous several years, many overseas young scientists in different fields were recruited into this lab. Subsequently, this lab was designated as the key lab of Sichuan Province and Ministry of Health of China in 1999 and 2002, respectively. In 2004, this group was honored as Innovative Research Team in University of Ministry of Education, China. The research works of this lab mainly focus on mechanism and intervention of graft dysfunction in allo- as well as xeno-transplantation. And exploring novel organ/tissue/cell resources for transplantation is another important direction of this lab. In recent 5 years, this group had gained several grants from Ministry of Science and Technology (973 and 863 program) and Natural Science Fund of China, and had published about one hundred papers in journals in the field of transplantation.
Research Focus and Work Team:
Direction 1: Chronic Graft Dysfunction (CGD)
Leading Researcher: Youping Li, MD, Professor
Researcher: Feng Li, PhD, Associate Professor; Shengfu Li, MD, Associate Professor
Research Interesting: CGD organ specificity, mechanism and intervention of CGD (Focus on endothelial cells and epithelial cells)
Direction 2: Pathology of Chronic Graft Injury
Leading Researcher: Hong Bu, PhD, Professor
Researcher: Shiyu Jun, PhD, Associate Professor; Li Zhang, PhD, Associate Professor
Research Interesting: Bioartificial liver and tissue engineering liver, the basic research of liver regeneration; relationship between micro-vascular remodeling/cell differentiation induction and chronic graft injury.
Direction 3: Biocompatibility of pig-human xenotransplantation
Leading Researcher: Jingqiu Cheng, PhD, Professor
Researcher: Yanrong Lu, PhD, Professor; Younan Chen, PhD, Associate Professor
Research Interesting:  Structure and function of coagulating and anti-coagulating factor of pig; pig to human pancreas/islet transplantation; Immunomodulation of MSC stem cells; pig to human bone transplantation.
Direction 4: Activated T cell depletion immunotoxins
Leading Researcher: Xiaofeng Lu, PhD, Professor
Researcher: Lin Wan, PhD, Assistant Professor; Hao Yang, Assistant Professor
Research Interesting: Cytokine and antibody-mediated immunotoxins target to activated T cells etc.
Contact Us
Director:  Professor Youping Li  Tel: 028-85164032 E-mail:
Vice-Director:  Associate Professor Li Zhang   Tel:028-85153958  E-mail:
Address: No.1, Keyuan 4th Road, High-tech District, Chengdu,Sichuan, 610041, P R China
2Laboratory of Stem Cell and Tissue Engineering
Founded in 1988, the Laboratory of Stem Cell and Tissue Engineering (LSCTE) of West China Hospital was the earliest of its type in China. It has become a Key Laboratory of MOH and MOE in 2002, part of the State Key Laboratory of Biotherapy in 2004, and part of the Regenerative Medicine Research Center in 2009. It now consists of four platforms including Tissue Culture and Cell Biology, Soft and Hard Tissue Histology, Biomaterials and Biomechanics, and has 10 full-time staffs including 3 PhD supervisors, 5 master student supervisors and 16 part-time research associates.
The LSCTE focuses on basic research as well as development of tissue engineering and regeneration products, with primary research goals including (1) separation, culture, identification, differentiation, safety evaluation and application of adult stem cells; (2) construction and implantation of tissue-engineered bone, tendon, skin, muscle and cartilage; (3) tissue engineering of cardiac muscle, esophagus, bladder and urethra, and (4) decellularized matrix biomaterials with the ability to induce stem cell differentiation and specify tissue regeneration.
During the past two decades, the LSCTE has accomplished a series of basic research as well as in vivo implantation animal experiments for tissue-engineered bone and tendons, which have won a First Prize for Innovation of Science and Technology by the MOE and a Second Prize of Science and Technology by the Chinese Medical Association. It has established technological standards and quality control for tissue-engineered bone, tendon and biomembrane, and transformed some of them into products. The laboratory in total has obtained 12 patents, published over 300 research papers and 10 books, and trained 2 postdocs, 39 PhD and 67 master students, and over 500 others in conjunct with other laboratories. Many papers have been published in highly ranked scientific journals such as Biomaterials, Bone, Stem Cell Reviews and Reports, etc. It has also formulated national standards for some products, and has rich experience in product transformation and registration. Through collaboration with two companies, 8 products have entered the stage of clinical trails, among which two have completed. Recently, two devices, namely Bio-derived bone substitute and Acellular bio-amniotic membrane, have been registered by the State Food and Drug Administration of China.
Full-time staff
Director: Zhi-ming Yang
Vice director: Hui-qi Xie
Investigators: Ting-wu Qin, Li Deng, Jing-cong Luo
Lab assistants: Xiao-he Chen, Xiu-qun Li, Yi Zhang, Lin Qiu, Wei Ding
Dr. Hui-qi Xie, Tel/Fax: +86 28 8516 4088, E-mail:
Other phone numbers:
Office: +86 28 8516 4088
Cell and Tissue Culture: +86 28 8516 4091
Histology: +86 28 8516 4089
Biomaterials: +86 28 8516 4090
Biomechanics: +86 28 8516 4090
3Laboratory of Cardiovascular Diseases Regenerative medicine research center, West China hospital, Sichuan University
Research Area: Cardiovascular diseases
Details: 1. Molecular, cellular and cell-biomechanics mechanism of cardiovascular diseases, such as atherosclerosis, coronary artery disease (CAD) and cardiac hypertrophy.
        2. Cardiac repair and remodeling.
3. Vascular biology and cell-biomechanics
Leading Researchers:  Prof. Chen Huaiqing, Prof. Liu Xiaojing, Prof. Li Liang, Prof. Chen Mao and Prof. Luo Fengming
Research Grants (as Principal Investigator):
1.        “A novel mechanism of mechanosensitive TRPC1 channel in cardiomyocyte hypertrophy”, No.11072163, (2011-2013), from the Chinese Natural Science Foundation.
2.        “Foxa2 and its regulating role in pulmonary defense mechanism”, No. 30971325, from the National Natural Science Foundation of China.
3.        “Foxa2 regulates the Th2 airway inflammation”, No.30871118, 2009~2011, from the National Natural Science Foundation of China.
4.        “Antigen presentation in airway smooth muscle”, No. 30500222, 2005~2008, from the National Natural Science Foundation of China.
5.        “Mechanical stimulation coupling with endoderm-derived developmental signals nodulate the transdifferentiation of amniotic epithelial cells into cardiomyocyte and its mechanism” No.30870596,(2008-2011),from the Chinese Natural Science Foundation.
6.        “Mechanical stimulation of heart beating modulates mesenchymal stem cell differentiation to cardiomyocyte and its mechanism” No. 3047437 (2005 ~ 2007), from the Chinese Natural Science Foundation.
Sichuan Province government in second-class scientific and technological progress Award: “Coronary heart disease critical illness early warning and individualized treatment study”(No. 2011-2-0305)
Cell biomechanics and clinical application, ISBN978-7-81106, Zhengzhou University Press, 2012. Editor in chief: Prof. Chen Huaiqing, Associated editors: Prof. Li Liang, Liu Xiaoheng and Liu Xiaojing
Recent publications:

1.  Wan Q, Zheng A, Liu X, Chen Y, Han L. Expression of transient receptor potential channel 6 in cervical cancer. Onco Targets Ther. 2012;5:171-6.

2.      Mao Chen, Xiao-Jing Liu, Shao-Di Yan, Yong Peng, Hua Chai, Qiao Li, Jia-Fu Wei, Yuan-Ning Xu, De-Jia Huang. Association between Cytochrome P450 2C19 polymorphism and clinical outcomes in the Chinese population with coronary artery disease. Atherosclerosis, 2012; 220: 168-171
3.      Zeng Y, Shen Y, Huang XL, Liu XJ, Liu XH. Roles of mechanical force and CXCR1/CXCR2 in shear-stress-induced endothelial cell migration. Eur Biophys J DOI 10.1007/s00249-011-0752-x
4.      Yan S, Chen M, Li Q, Liu X, Peng Y, Chai H, Xu YN, Wei J and Huang D. The Value of Combining CYP2C19*2 Polymorphism with Classic Risk Factors in Prediction of Clinical Prognosis in Acute Coronary Syndrome Patients. Cardiology 2011; 119:15-20 (IF:1.982)
5.      Peng Y, Chen M, Chai H, Liu X, Yan S, Li Q, Wei J, Xu YN, Wu W and Huang D. Impact of combination of calcium-channel blockers with clopidogrel on clinical outcomes in patients with coronary artery disease. Int J Cardiol 2011;149:174-6 (IF:6.802)
6.      Fu H, Luo F, Yang L, Wu W and Liu X. Hypoxia stimulates the expression of macrophage migration inhibitory factor in human vacular smooth muscle cells via the HIF-1a dependent pathway. BMC Cell Biol 2010; 11;66
7.      Pan P, Fu H, Zhang L, Huang H, Luo F, Wu W, Guo Y and Liu X. Angiotensin II upregulates the expression of placental growth factor in human vascular endothelial cells and smooth muscle cells. BMC Cell Biol 2010; 11:36
8.      Li J, Liu X, Ran X, Chen J, Li X, Wu W, Huang H, Huang H, Long Y, Liang J, Cheng J and Tian H.. Sterol regulatory element-binding protein-1c knockdown protected INS-1E cells from lipotoxicity. Diabetes Obes Metab 2010;12(1):35-46.
9.      Liu X , Ji Y, Chen J, Li S, Luo F. Circulating visfatin in chronic obstructive pulmonary. Nutrition, 2009; 25: 373 (IF:2.28)
10.  Ge D, Liu X , Li L, Wu J, Tu Q, Shi Y, Chen H. Chemical and physical stimuli induce cardiomyocyte differentiation from stem cells. Biochem Biophys Res Commun 2009:381:317 (IF:2.65)
11.  Liu X, Luo F, Li J, Wu W, Li L, Chen H. Homocysteine induces connective tissue growth factor expression in vascular smooth muscle cells. J Thromb Haemost. 2008;6:184-192
12.  Liu X, Luo F, Pan K, Wu W, Chen H. High glucose upregulates connective tissue growth factor expression in human vascular smooth muscle cells. BMC Cell Biol 2007; 8:1 (IF:2.74)
13.  Chen M, Fan Z, Liu X, Dneg J, Yang Q, Huang D.. Cell transplantation with a catheter-based approach: an efficient method for the treatment of heart failure with multiple lesions. Cell Prolif  2006;39:471-477.
14.  Chen M , Fan Z, Liu X , Deng J, Zhang L, Rao L, Yang Q, Huang D . Effects of autologous stem cell transplantation on ventricular electrophysiology in doxorubicin- induced heart failure. Cell Biology International 2006;30:576-582.
15.  Luo F, Liu X, Wang S, Chen H. Effect of homocysteine on platelet activation induced by collagen. Nutrition. 2006 ;22(1):69-75.
16.  Luo F, Liu X, Yan N, Li S, Cao G, Cheng Q, Xia Q, Wang H. Hypoxia-inducible transcription factor-1alpha promotes hypoxia-induced A549 apoptosis via a mechanism that involves the glycolysis pathway. BMC Cancer. 2006; 6(1):26
17.  Luo F, Liu X, Li S, Wang Z, Liu C, Yuan Y. Circulating Ghrelin in Patients with Chronic Obstructive Pulmonary Disease. Nutrition ;2005; 21:793
18.  Luo F, Liu X, Li S, Liu C, Wang Z. Melatonin promoted chemotaxins expression in lung epithelial cell stimulated with TNFa. Respiratory Research, 2004; 5:20
19.  Liu X, Sahud MA. Glycoprotein IIb/IIIa complex is the taqrget in mirtazapine- induced immune thrombocytopenia. Blood Cells, Molecules, and Diseases, 2003; 30: 241-245 (IF: 2.549)
4Laboratory of Ethnopharmacology
Laboratory of Ethnopharmacology was founded in 2009 as the key laboratory of Clinical Chinese Medicine integrated with Western Medicine of Sichuan province. Clinical Chinese Medicine integrated With western Medicine was awarded as national key discipline.
At present, it houses 5 full-time researchers including 3 advanced level professionals, 2 medium level professionals. Among them, 2 are doctoral supervisors and 3 are master supervisors. Current, the laboratory has 1 post-doctor, 4 graduate students for doctoral degrees and 9 for master’s degrees, 2 of them are now studying abroad sponsored by national construction of high-level university program.
The laboratory consists of the traditional chinese medicine (TCM) active ingredient pharmacological and safety research unit, the TCM active ingredient screening research unit, the animal models of disease and pharmacology methodology research unit, the TCM pharmacokinetics research unit, and the biochemistry/medicinal-chemistry research unit. The laboratory presently takes up space of about 700 m2, possesses 160 units of advanced instruments and equipments which worth more than 7 million RMB.
The laboratory has been focusing on the basic and applied research of traditional chinese medicine pharmacology. The major research areas cover pharmacology and drug development, innovation of Chinese medicine theories and pharmacological evaluation, traditional Chinese medicine pharmacokinetics, animal models of disease and traditional Chinese medicine pharmacological methods. The laboratory has the abundant technical strength, especially in the fields of pharmacology and drug development, and traditional Chinese medicine pharmacokinetics.
In recent years, the laboratory has taken charge of a range of research projects such as: National "11th Five-Year Plan" and "12th Five-Year Plan" subprojects, National Natural Science Foundation projects, Beijing Municipal Committee of Science and Technology projects, Doctoral Scientific Fund Project of the Ministry of Education, and projects supported by Sichuan province. Total finacial supports from these scientific projects exceed 6 million RMB. Up to now, more than 50 SCI papers have been published and 12 patents are applied.
Principal Telephone E-mail
Zhihua Xing 02885164075
Dan Du 02885164075
5Laboratory of Endocrinology and Metabolism

Laboratory of Endocrinology and Metabolism was founded in 1980. Our laboratory is a pioneering centre in China which combines research, patient education and clinical trial in diabetes, osteoporosis and some other endocrine and metabolic disorders. Our laboratory aims to establish novel biomarkers for early diagnosis, and develop therapeutic targets for these disorders.
Major research area
l  Osteoporosis
l  Novel endocrine functions of skeletal system
l  Molecular mechanism of diabetes and other endocrine and metabolic disorders
Research team member
Director: Xijie Yu, M.D., Ph.D, Professor and Director
Research staff: Mingde Fu, Xiang Chen, Meng Gong
Technical staff: Yang Long, Xiangxun Zhang, Hongling Yu
Research platform
1. Cell and molecular biology technology platform
2. Genetically engineered mice platform
3. Metabolic platform
Grants from the National Natural Science Foundation of China
1.      Molecular genetic mechanisms of bone disorders in in Neurofibromatosis Type 1 (No. 30872632)
2.      The regulations of microRNAs in bone metastasis in human lung cancer (No. 81072190)
3.      Reciprocal regulation of peroxisome proliferator-activated receptor alpha and glucocorticoid receptor forms a new negative feedback loop (No. 30700379)
4.      Study of yeast expression system, antivirus mechanism and recombination active peptides of an antiviral protein (No.30900244)
5.      The pathological roles of microRNAs in carcinogenesis in malignant peripheral nerve sheath tumors (No. 81101920)
Selected publications within past three years
1.        Meng Gong, Junrong Ma, Mi Li, Mingliang Zhou, Janet M. Hock, Xijie Yu. MicroRNA-204 Critically Regulates Carcinogenesis in Malignant Peripheral Nerve Sheath Tumors. NEURO-ONCOLOGY. 2012;14(8):1007–1017.
2.        Xiang Chen, Haoming Tian, Xijie Yu. Bone Delivers Its Energy Information to Fat and Islets Through Osteocalcin. Orthopaedic Surgery. 2012;4:114-117.
3.        Emily Farrow, Xijie Yu, Lelia Summers, Siobhan Davis, James Fleet, Matthew Allen, Alexander Robling, Keith Stayrook, Victoria Jideonwo, Martin Magers, Holly Garringer, Ruben Vidal, Rebecca Chan, Charles Goodwin, Siu Hui, Munro Peacock, Kenneth White. Altered Fgf23 Proteolytic Regulation Causes Lateonset Hypophosphatemia During Iron Deficiency in an ADHR Mouse Model. Proceedings of the National Academy of Sciences of the United States of America.2011;108(46):E1146-55.
4.        Mi Li, Mingliang Zhou, Meng Gong, Junrong Ma, Fuxing Pei, Wesley G. Beamer, Janet M. Hock, Xijie Yu. A Novel Animal Model for Bone Metastasis in Human Lung Cancer. Oncology Letters. 2012; 13(3): 802-806.
5.        Junrong Ma, Mi Li, Janet Hock, Xijie Yu. Hyperactivation of mTOR Critically Regulates Abnormal Osteoclastogensis in Neurofibromatosis Type 1. Journal of Orthopaedic Research. 2012; 30(1): 14-152.
6.        Tian Xia, Yanhua Liang, Junrong Ma, Mi Li, Meng Gong, Xijie Yu. Loss-of-Function of SHARPIN Causes an Osteopenic Phenotype in Mice. Endocrine, 2011; 39,104-112.
7.        Li Tian, Yanhua Xu, Mingde Fu, Tao Peng, Yinghui Liu, Shiyin Long. The impact of plasma triglyceride and apolipoproteins concentrations on high-density lipoprotein subclasses distribution. Lipids in Health and Disease 2011; 10:17.
8.        Li Tian, Shiyin Long Mingde Fu, Yinghui Liu, Yanhua Xu and Lianqun Jia. Characteristics of high-density lipoprotein subclasses distribution for subjects with desirable total cholesterol levels. Lipids in Health and Disease 2011, 10:64
9.        Li Tian and Mingde Fu. The relationship between high density lipoprotein subclass profile and apolipoprotein concentrations. J. Endocrinol. Invest. 2011; 34: 461-472.
10.    Gong, M., Xia, M., Zhang, J., Gu, J., Liu, X., and Cheng, J. A novel anti-lymphoma protein RE26 from Rozites emodensis (Berk) Moser. Appl Microbiol Biotechnol, 2012; 93, 1097-1108.
Contact information:
Contact: Professor Xijie Yu
Tel 028-85422362
News & Events Center

Powered by West China Hospital,Sichuan University / West China Hospital of Medicine, Sichuan University © 2004-2013 Inc.

Copyright 2013 West China Hospital,Sichuan University / West China Hospital of Medicine, Sichuan University Add: No. 37 Guo Xue Xiang, Chengdu, Sichuan, 610041, P.R. China